Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT06385080
Title	A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Recurrent/Metastatic Head and Neck Cancer (OrigAMI-4)
Acronym	OrigAMI-4
Recruitment	Recruiting
Gender	both
Phase	Phase Ib/II
Variant Requirements	Yes
Sponsors	Janssen Research & Development, LLC
Indications	laryngeal squamous cell carcinoma oropharynx cancer head and neck squamous cell carcinoma oral squamous cell carcinoma hypopharynx cancer
Therapies	Amivantamab-vmjw Amivantamab-vmjw + Pembrolizumab Amivantamab-vmjw + Paclitaxel
Age Groups:	adult \| senior
Covered Countries	USA \| GBR